CAPR (Capricor Therapeutics) EPS without NRI: $-2.49 (TTM As of Mar. 2026)


CAPR Capricor Therapeutics Inc CAPR
37 GF Score
Price $24.75
GF Value $4.87
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Capricor Therapeutics EPS without NRI?

Capricor Therapeutics CAPR +3.99% 37 EPS without NRI is $-2.49 as of Mar. 2026. GuruFocus rates CAPR with a GF Score™ of 37/100 and a GF Value™ of $4.87 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,172 Biotechnology companies, Capricor Therapeutics ranks worse than 88.99% on this metric.

Capricor Therapeutics's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $-0.64. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.49.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -25.80% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -17.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Capricor Therapeutics's EPS without NRI or its related term are showing as below:

CAPR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -848   Med: 15.25   Max: 76
Current: -25.8

During the past 13 years, Capricor Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 76.00% per year. The lowest was -848.00% per year. And the median was 15.25% per year.

CAPR's 3-Year EPS without NRI Growth Rate is ranked worse than
88.99% of 1172 companies
in the Biotechnology industry
Industry Median: 16.8 vs CAPR: -25.80

Capricor Therapeutics's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.59. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.32.

Capricor Therapeutics's EPS (Basic) for the three months ended in Mar. 2026 was $-0.59. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.32.


Capricor Therapeutics  (NAS:CAPR) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Capricor Therapeutics EPS without NRI Related Terms


Capricor Therapeutics EPS without NRI Historical Data

* Premium members only.

The historical data trend for Capricor Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Capricor Therapeutics EPS without NRI Chart

Capricor Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.89 -1.20 -0.89 -1.21 -2.39

Capricor Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.54 -0.61 -0.58 -0.66 -0.64

CAPR vs COAG, DMRA, MPLT: EPS without NRI Comparison

For the Biotechnology subindustry, Capricor Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Capricor Therapeutics PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Capricor Therapeutics's PE Ratio without NRI falls into.


CAPR
37GF Score
Capricor Therapeutics Inc CAPR
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Capricor Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-2.49 mean?
Capricor Therapeutics (CAPR) has a EPS without NRI of $-2.49 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Capricor Therapeutics and its competitors. According to the industry distribution chart, Capricor Therapeutics ranks #1043 out of 1172 companies in the Biotechnology industry, placing it in the top 89%.
Is Capricor Therapeutics' EPS without NRI too high?
Capricor Therapeutics' current EPS without NRI is $-2.49. Based on the distribution chart, Capricor Therapeutics ranks #1043 out of 1172 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Capricor Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Capricor Therapeutics' EPS without NRI compare to COAG and DMRA?
According to the Biotechnology industry distribution chart, Capricor Therapeutics ranks #1043 out of 1172 companies for EPS without NRI. This places Capricor Therapeutics in the lower half of its industry. The industry median EPS without NRI is 16.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.80, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Capricor Therapeutics and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Capricor Therapeutics's current EPS without NRI is $-2.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Capricor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Capricor Therapeutics (CAPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.87, compared to a current price of $24.75 — trading 408.2% above its estimated fair value. The current EPS without NRI is $-2.49. Capricor Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Capricor Therapeutics (CAPR), the current EPS without NRI is $-2.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Capricor Therapeutics (CAPR) Overvalued in 2026?

Based on GuruFocus' analysis, Capricor Therapeutics stock appears to be overvalued. The current stock price of $24.75 is trading 408.2% above its estimated GF Value™ of $4.87. GuruFocus considers Capricor Therapeutics to be Significantly Overvalued.

Key valuation signals for CAPR:

  • EPS without NRI: $-2.49
  • GF Value™: $4.87 vs. price of $24.75 (408.2% above fair value)
  • GF Score™: 37/100 with 3 warning signs

No single metric tells the full story. See the CAPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Capricor Therapeutics Business Description

Other Exchanges 4LN2:Germany
Address 10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
37GF Score

Get the complete analysis for CAPR

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.75
Price
$4.87
GF Value